Humanin

Humanin is a 24-amino-acid peptide with the sequence Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala and a molecular weight of approximately 2,687 Da. It was discovered in 2001 by Hashimoto et al. through a functional expression screen of a cDNA library derived from the occipital cortex of an Alzheimer's disease patient. Humanin holds the distinction of being the first peptide identified as being encoded by mitochondrial DNA (specifically the 16S ribosomal RNA gene, MT-RNR2) rather than nuclear DNA, establishing the concept of mitochondrial-derived peptides (MDPs) as a new class of bioactive signaling molecules.

Humanin exerts cytoprotective effects through multiple intracellular and extracellular mechanisms. Intracellularly, it directly binds the pro-apoptotic Bcl-2 family members Bax and BID, preventing their oligomerization and insertion into the mitochondrial outer membrane. This blocks cytochrome c release and prevents activation of the caspase-9/caspase-3 apoptotic cascade. Extracellularly, humanin binds to a trimeric receptor complex consisting of CNTFR (ciliary neurotrophic factor receptor), WSX-1 (IL-27 receptor alpha), and gp130. Activation of this receptor complex triggers JAK2/STAT3 signaling, which upregulates anti-apoptotic genes including Bcl-2 and Mcl-1. Humanin also binds IGFBP-3 and modulates IGF-1 signaling, adding another layer to its pro-survival activity.

Population-based studies have revealed a striking association between circulating humanin levels and longevity. A cohort study published in Aging Cell by Muzumdar et al. showed that centenarians have circulating humanin levels 2-3 times higher than age-matched (70-80 year old) controls. Children of centenarians also have significantly elevated humanin levels compared to age-matched controls whose parents had normal lifespans, suggesting a heritable component to humanin production. These epidemiological findings are consistent with the hypothesis that mitochondrial-derived peptides serve as retrograde signals communicating mitochondrial health status to the rest of the cell and organism.

The S14G substitution analog, known as [Gly14]-Humanin or HNG, replaces the serine at position 14 with glycine, dramatically increasing potency. The EC50 of HNG in neuroprotection assays is approximately 0.1 nM compared to approximately 100 nM for native humanin, representing a 1,000-fold improvement. This potency enhancement was discovered through systematic alanine-scanning mutagenesis and is thought to result from improved receptor binding kinetics. HNG retains all of native humanin's cytoprotective mechanisms while requiring substantially lower concentrations.

Beyond neuroprotection, humanin and HNG have demonstrated metabolic benefits in preclinical models. Intraperitoneal administration of HNG improved insulin sensitivity and glucose tolerance in high-fat diet-fed mice, reducing fasting glucose levels and improving insulin-stimulated glucose uptake in muscle and adipose tissue. These effects are mediated in part through STAT3-dependent enhancement of insulin receptor substrate (IRS) signaling. Humanin also reduces atherosclerotic plaque formation: ApoE-knockout mice treated with HNG showed reduced aortic lesion area and decreased macrophage infiltration in plaques.

Humanin protects against ischemia-reperfusion injury in cardiac tissue. Studies published in the Journal of Molecular and Cellular Cardiology showed that humanin pre-treatment reduced myocardial infarct size by 30-40% in rat models of coronary occlusion. The cardioprotective mechanism involves STAT3 activation and mitochondrial permeability transition pore (mPTP) inhibition, preventing the catastrophic mitochondrial depolarization that drives cardiomyocyte death during reperfusion.

For reconstitution and storage, lyophilized humanin peptides should be reconstituted with sterile water and stored at 2-8 degrees C. Reconstituted solutions should be used within 14 days or aliquoted and stored at -20 degrees C. Lyophilized powder is stable at -20 degrees C for extended periods. Humanin is soluble in water and does not require organic co-solvents. Avoid repeated freeze-thaw cycles, as the peptide contains a cysteine residue (Cys8) that can form intermolecular disulfide bonds leading to aggregation.

The safety profile of humanin and analogs in preclinical studies has been favorable. No toxicity has been observed in rodent studies at doses producing clear pharmacological effects. The endogenous nature of humanin, its presence in measurable concentrations in human plasma, and its association with healthy aging and longevity all support a favorable risk profile. However, no human clinical trials of exogenous humanin administration have been completed to date, so formal clinical safety data remain limited.